Advertisement


Howard M. Sandler, MD, Summarizes Results of the RTOG 0521 Trial on Localized, High-Risk Prostate Cancer

2015 ASCO Annual Meeting

Advertisement

Howard M. Sandler, MD, of Cedars-Sinai Medical Center discusses the improvement of overall survival with the use of adjuvant chemotherapy following androgen suppression and radiotherapy (Abstract LBA5002).



Related Videos

Breast Cancer

Nicholas C. Turner, MD, PhD, Summarizes Results of the PALOMA3 Breast Cancer Study

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital NHS Trust, discusses fulvestrant and palbociclib as a treatment option in pre- and postmenopausal women with hormone receptor–positive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy (Abstract LBA502).

Issues in Oncology
Cost of Care

Charles L. Bennett, MD, PhD, MPP, and James O. Armitage, MD, on Biosimilars in Oncology

Charles L. Bennett, MD, PhD, MPP of the University of South Carolina College of Pharmacy, and James O. Armitage, MD, of the University of Nebraska Medical Center, discuss the emerging and future benefits of biosimilars.

Head and Neck Cancer

Anil D'Cruz, MD, on Elective Neck Dissection in Node-Negative Early Oral Cancer

Anil D’Cruz, MD, of Tata Memorial Hospital, discusses results from his study that seem to resolve a 50-year-long debate on performing elective neck dissection at the time of primary surgery––a potentially practice-changing finding (Abstract LBA3).

Global Cancer Care
Health-Care Policy

Lawrence N. Shulman, MD, and Clifford A. Hudis, MD, on Cancer Care in Resource-Challenged Areas

Lawrence N. Shulman, MD, of Dana-Farber Cancer Institute, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss the delivery of cancer care in resource-constrained settings such as Rwanda and Haiti, and plans to conduct research in basic tumor biology of patients in these areas.

Breast Cancer

Richard G. Margolese, MD, and Robert W. Carlson, MD, on NSABP B-35 Trial Results for Postmenopausal Women With DCIS

Robert W. Carlson, MD, of the National Comprehensive Cancer Network, and Richard G. Margolese, MD, of McGill University, discuss the improvement in breast cancer–free interval with anastrozole vs tamoxifen in patients with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (Abstract LBA500).

Advertisement

Advertisement




Advertisement